Dan Ioanes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dan Ioanes has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Oskar Angerås
Department of Cardiology, Sahlgrenska University Hospital, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden (D.I., O.A.).
5 shared publications - Jacob Lønborg
Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Denmark (J.L.).
4 shared publications - Reza Jabbari
Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Denmark (J.M.M., C.G., R.J., M. Sabbah, L.H., R.S., G.B., T.H.J., O.D.B., T.E., J.L.).
4 shared publications - Rikke Sørensen
Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Denmark (J.M.M., C.G., R.J., M. Sabbah, L.H., R.S., G.B., T.H.J., O.D.B., T.E., J.L.).
4 shared publications Sasha Koul
Department of Cardiology, Lund University, Skåne University Hospital, Sweden (S.K.).
4 shared publications- Thomas Engstrøm
Rigshospitalet, University of Copenhagen, Denmark (T.E.).
4 shared publications
Latest Publications
- 1 September 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (9)
Impact of Coronary Diameter Stenosis and Proximal Lesion Location on Outcomes Following PCI in Patients Undergoing TAVI: Prespecified NOTION-3 Substudy
BACKGROUND: Optimal treatment of coronary artery disease in patients undergoing transcatheter aortic valve implantation remains debated. Here, our aim was to analyze the impact of the diameter and location of coronary stenosis on outcomes in patients undergoing percutaneous coronary intervention (PCI) with transcatheter aortic valve implantation. METHODS: This study was a prespecified subanalysis of the NOTION-3 trial (Nordic Aortic Valve Intervention), which randomized patients with severe symptomatic aortic stenosis and physiologically significant stable coronary artery disease to receive either PCI or conservative treatment of coronary artery disease with transcatheter aortic valve implantation. In this substudy, patients were stratified according to diameter stenosis (P for interaction=0.051). PCI reduced major adverse cardiovascular events in case of proximal stenosis (26% versus 38%; hazard ratio, 0.61 [95% CI, 0.40–0.93]), although the difference in effect remained nonsignificant when compared with patients with nonproximal stenosis (28% versus 32%; hazard ratio, 0.91 [95% CI, 0.52–1.61]; P for interaction=0.27). CONCLUSIONS: The beneficial effect of PCI in patients undergoing transcatheter aortic valve implantation with physiologically significant stable coronary artery disease was seemingly pronounced in patients with high-grade stenosis, while stenosis location was not found to modify the outcome despite an almost similar beneficial effect with PCI in patients with proximal stenosis.
- 1 September 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (9)
Impact of Coronary Diameter Stenosis and Proximal Lesion Location on Outcomes Following PCI in Patients Undergoing TAVI: Prespecified NOTION-3 Substudy
BACKGROUND: Optimal treatment of coronary artery disease in patients undergoing transcatheter aortic valve implantation remains debated. Here, our aim was to analyze the impact of the diameter and location of coronary stenosis on outcomes in patients undergoing percutaneous coronary intervention (PCI) with transcatheter aortic valve implantation. METHODS: This study was a prespecified subanalysis of the NOTION-3 trial (Nordic Aortic Valve Intervention), which randomized patients with severe symptomatic aortic stenosis and physiologically significant stable coronary artery disease to receive either PCI or conservative treatment of coronary artery disease with transcatheter aortic valve implantation. In this substudy, patients were stratified according to diameter stenosis (P for interaction=0.051). PCI reduced major adverse cardiovascular events in case of proximal stenosis (26% versus 38%; hazard ratio, 0.61 [95% CI, 0.40–0.93]), although the difference in effect remained nonsignificant when compared with patients with nonproximal stenosis (28% versus 32%; hazard ratio, 0.91 [95% CI, 0.52–1.61]; P for interaction=0.27). CONCLUSIONS: The beneficial effect of PCI in patients undergoing transcatheter aortic valve implantation with physiologically significant stable coronary artery disease was seemingly pronounced in patients with high-grade stenosis, while stenosis location was not found to modify the outcome despite an almost similar beneficial effect with PCI in patients with proximal stenosis.
- Open Access
- 16 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Valvular and Structural Heart Disease
- Vol. 2 (3)
Baseline Angina in Patients with Severe Aortic Stenosis and Coronary Artery Disease: A Secondary Analysis of the NOTION-3 Randomized Controlled Trial
Background: Angina is common in patients with coronary artery disease and severe aortic stenosis. Whether angina should guide coronary revascularization in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) remains uncertain. Aims: To assess whether angina modifies the effect of percutaneous coronary intervention (PCI) on clinical outcomes and whether percutaneous coronary intervention influences angina burden after TAVI. Methods and results: This prespecified secondary analysis of the NOTION-3 trial included patients with severe aortic stenosis and significant coronary artery disease randomized to TAVI with percutaneous coronary intervention or optimal medical therapy (OMT). Baseline angina was assessed by Seattle Angina Questionnaire-7 Angina Frequency score, supplemented by Canadian Cardiovascular Society class when questionnaire data were missing. Of 454 patients, 229 (50%) had angina and 225 (50%) had no angina. In the baseline angina subgroup, the primary outcome MACE, a composite of death from any cause, myocardial infarction, or urgent revascularization, occurred in 27% randomized to PCI versus 37% randomized to OMT. Without angina, rates were 26% versus 35%. Hazard ratios for PCI versus OMT were 0.71 (95%-CI 0.45–1.13) in patients with angina and 0.69 (95%-CI 0.43–1.12) in those without, with no interaction by baseline angina (P=0.97). SAQ-7 summary scores improved at 1 year in angina groups, with no between-group difference in change (16 vs. 17; P=0.78). Conclusion: We found no evidence that baseline angina modified the relative effect of PCI on clinical outcomes, although the study was not powered to exclude clinically meaningful heterogeneity.
- 16 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Valvular and Structural Heart Disease
- Vol. 2 (3)
Open AccessBaseline Angina in Patients with Severe Aortic Stenosis and Coronary Artery Disease: A Secondary Analysis of the NOTION-3 Randomized Controlled Trial
Background: Angina is common in patients with coronary artery disease and severe aortic stenosis. Whether angina should guide coronary revascularization in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) remains uncertain. Aims: To assess whether angina modifies the effect of percutaneous coronary intervention (PCI) on clinical outcomes and whether percutaneous coronary intervention influences angina burden after TAVI. Methods and results: This prespecified secondary analysis of the NOTION-3 trial included patients with severe aortic stenosis and significant coronary artery disease randomized to TAVI with percutaneous coronary intervention or optimal medical therapy (OMT). Baseline angina was assessed by Seattle Angina Questionnaire-7 Angina Frequency score, supplemented by Canadian Cardiovascular Society class when questionnaire data were missing. Of 454 patients, 229 (50%) had angina and 225 (50%) had no angina. In the baseline angina subgroup, the primary outcome MACE, a composite of death from any cause, myocardial infarction, or urgent revascularization, occurred in 27% randomized to PCI versus 37% randomized to OMT. Without angina, rates were 26% versus 35%. Hazard ratios for PCI versus OMT were 0.71 (95%-CI 0.45–1.13) in patients with angina and 0.69 (95%-CI 0.43–1.12) in those without, with no interaction by baseline angina (P=0.97). SAQ-7 summary scores improved at 1 year in angina groups, with no between-group difference in change (16 vs. 17; P=0.78). Conclusion: We found no evidence that baseline angina modified the relative effect of PCI on clinical outcomes, although the study was not powered to exclude clinically meaningful heterogeneity.
- 26 May 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (21) , 1687-1690
Impact of Angina on Outcome After Percutaneous Coronary Intervention in Patients Undergoing Transcatheter Aortic Valve Implantation: Insights From the NOTION-3 Trial
- 26 May 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (21) , 1687-1690
Impact of Angina on Outcome After Percutaneous Coronary Intervention in Patients Undergoing Transcatheter Aortic Valve Implantation: Insights From the NOTION-3 Trial
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (4) , e016337
PCI Versus Conservative Management Before TAVR in Patients With Significant Coronary Artery Disease: A Nationwide Instrumental Variable Analysis
BACKGROUND: The optimal management of coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) remains unclear, and evidence supporting routine percutaneous coronary intervention (PCI) beforehand is limited. This study aimed to evaluate whether PCI before TAVR provides clinical benefit compared with conservative management in patients with significant coronary artery disease, using nationwide Swedish registry data. METHODS: This observational study included 2578 Swedish patients with significant coronary artery disease (≥50% angiographic stenosis or physiologically significant lesions) who underwent TAVR between 2008 and 2023. 1182 underwent PCI before TAVR, and 1396 were managed conservatively. The primary outcome was a composite of all-cause mortality, myocardial infarction, and urgent revascularization. Secondary outcomes included the individual components, cardiovascular mortality, any revascularization, stroke, and bleeding. The primary analysis used an instrumental variable approach based on each region’s quarterly PCI treatment preference to account for confounding. RESULTS: PCI was not associated with a significant difference in the primary composite outcome (instrumental variable–adjusted hazard ratio, 0.98 [95% CI, 0.85–1.14]; P =0.80) or in all-cause mortality, myocardial infarction, cardiovascular death, stroke, or urgent revascularization. PCI was, however, associated with a lower risk of any revascularization (adjusted hazard ratio, 0.46 [95% CI, 0.30–0.72]; adjusted P =0.002) and a higher risk of bleeding (instrumental variable–adjusted odds ratio, 1.59 [95% CI, 1.23–2.04]; adjusted P =0.002). CONCLUSIONS: In this nationwide cohort, PCI before TAVR did not improve survival or reduce urgent revascularization but did reduce nonurgent revascularization at the cost of increased bleeding. Decisions should be individualized, balancing ischemic and bleeding risks and considering anticipated coronary access after TAVR.
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (4) , e016337
PCI Versus Conservative Management Before TAVR in Patients With Significant Coronary Artery Disease: A Nationwide Instrumental Variable Analysis
BACKGROUND: The optimal management of coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) remains unclear, and evidence supporting routine percutaneous coronary intervention (PCI) beforehand is limited. This study aimed to evaluate whether PCI before TAVR provides clinical benefit compared with conservative management in patients with significant coronary artery disease, using nationwide Swedish registry data. METHODS: This observational study included 2578 Swedish patients with significant coronary artery disease (≥50% angiographic stenosis or physiologically significant lesions) who underwent TAVR between 2008 and 2023. 1182 underwent PCI before TAVR, and 1396 were managed conservatively. The primary outcome was a composite of all-cause mortality, myocardial infarction, and urgent revascularization. Secondary outcomes included the individual components, cardiovascular mortality, any revascularization, stroke, and bleeding. The primary analysis used an instrumental variable approach based on each region’s quarterly PCI treatment preference to account for confounding. RESULTS: PCI was not associated with a significant difference in the primary composite outcome (instrumental variable–adjusted hazard ratio, 0.98 [95% CI, 0.85–1.14]; P =0.80) or in all-cause mortality, myocardial infarction, cardiovascular death, stroke, or urgent revascularization. PCI was, however, associated with a lower risk of any revascularization (adjusted hazard ratio, 0.46 [95% CI, 0.30–0.72]; adjusted P =0.002) and a higher risk of bleeding (instrumental variable–adjusted odds ratio, 1.59 [95% CI, 1.23–2.04]; adjusted P =0.002). CONCLUSIONS: In this nationwide cohort, PCI before TAVR did not improve survival or reduce urgent revascularization but did reduce nonurgent revascularization at the cost of increased bleeding. Decisions should be individualized, balancing ischemic and bleeding risks and considering anticipated coronary access after TAVR.
- Open Access
- 24 March 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Valvular and Structural Heart Disease
- Vol. 2 (2)
Assessing the impact of age on outcomes following percutaneous coronary intervention in patients undergoing transcatheter aortic valve replacement—a substudy in NOTION-3
Background: Findings from the recent NOTION-3 trial suggest that percutaneous coronary intervention (PCI) improves outcomes in patients with severe aortic stenosis and concomitant coronary artery disease undergoing transcatheter aortic valve implantation (TAVI). Whether the benefit of PCI is consistent across age groups is uncertain. Aims: To investigate the impact of age on outcomes from NOTION-3. Methods: A secondary analysis of 455 patients in the NOTION-3 trial, a randomized trial comparing PCI with conservative treatment in patients with aortic stenosis and coronary artery disease undergoing TAVI. Patients were stratified into four age groups based on the quartile distribution of age (<78, 78–81, 82–84, and ≥85 years) and followed for a median of 2 years (IQR: 1–4 years). The primary outcome was major adverse cardiac events defined as a composite of all-cause death, myocardial infarction, or urgent revascularization. Results: The risk difference for the primary endpoint comparing PCI and conservative treatment was most pronounced in patients aged 78–81 years [17% vs 42%; hazard ratio (HR): 0.36, 95% confidence interval (CI): 0.17–0.77, P = .008]. For the age groups <78, 82–84 and ≥85 years this risk difference between treatment groups was (HR: 1.08, 95% CI: 0.48–2.40), (HR: 0.69, 95% CI: 0.35–1.35), and (HR: 0.90, 95% CI: 0.50–1.62), respectively. Conclusion: In patients with coronary artery disease undergoing TAVI the benefit of PCI compared with conservative treatment on the composite of all-cause death, myocardial infarction, or urgent revascularization was most pronounced among patients aged 78–84 years.
- 24 March 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Valvular and Structural Heart Disease
- Vol. 2 (2)
Open AccessAssessing the impact of age on outcomes following percutaneous coronary intervention in patients undergoing transcatheter aortic valve replacement—a substudy in NOTION-3
Background: Findings from the recent NOTION-3 trial suggest that percutaneous coronary intervention (PCI) improves outcomes in patients with severe aortic stenosis and concomitant coronary artery disease undergoing transcatheter aortic valve implantation (TAVI). Whether the benefit of PCI is consistent across age groups is uncertain. Aims: To investigate the impact of age on outcomes from NOTION-3. Methods: A secondary analysis of 455 patients in the NOTION-3 trial, a randomized trial comparing PCI with conservative treatment in patients with aortic stenosis and coronary artery disease undergoing TAVI. Patients were stratified into four age groups based on the quartile distribution of age (<78, 78–81, 82–84, and ≥85 years) and followed for a median of 2 years (IQR: 1–4 years). The primary outcome was major adverse cardiac events defined as a composite of all-cause death, myocardial infarction, or urgent revascularization. Results: The risk difference for the primary endpoint comparing PCI and conservative treatment was most pronounced in patients aged 78–81 years [17% vs 42%; hazard ratio (HR): 0.36, 95% confidence interval (CI): 0.17–0.77, P = .008]. For the age groups <78, 82–84 and ≥85 years this risk difference between treatment groups was (HR: 1.08, 95% CI: 0.48–2.40), (HR: 0.69, 95% CI: 0.35–1.35), and (HR: 0.90, 95% CI: 0.50–1.62), respectively. Conclusion: In patients with coronary artery disease undergoing TAVI the benefit of PCI compared with conservative treatment on the composite of all-cause death, myocardial infarction, or urgent revascularization was most pronounced among patients aged 78–84 years.
- Open Access
- 24 October 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 8 (11) , ytae577
Navitor™ in Evolut™: a case report illustrating a novel approach to redo-transcatheter aortic valve implantation
Transcatheter aortic valve implantation (TAVI) is expanding to younger patients and the management of valve failure is a growing clinical problem. The transcatheter heart valve (THV) of choice for redo - TAVI is a complex decision and first reports have examined the use of the Sapien 3TM THV (Edwards Lifesciences; Irvine, CA, USA) in failed EvolutTM (Medtronic, Minneapolis, MN, USA) THV. However, several different technical approaches may be worth consideration, and the subject remains a matter of debate. A 73-year old female with previous coronary artery by-pass grafting (CABG), percutaneous coronary intervention (PCI) and TAVI with a 26 mm EvolutTM R THV presented with signs of heart failure. The clinical investigation revealed a severe restenosis of the THV valve and a stenosis of the left coronary main stem. The patient was successfully treated with PCI of the left main and, during the same procedure, underwent implantation of a 25 mm NavitorTM THV (Abbott; Chicago, Il, USA). This case presentation aims to illustrate the rationale of and necessary conditions for performing a TAVI-in-TAVI procedure with NavitorTM THV in a failed EvolutTM THV which, to our best knowledge, constitutes a novel approach to redo - TAVI.
- 24 October 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 8 (11) , ytae577
Open AccessNavitor™ in Evolut™: a case report illustrating a novel approach to redo-transcatheter aortic valve implantation
Transcatheter aortic valve implantation (TAVI) is expanding to younger patients and the management of valve failure is a growing clinical problem. The transcatheter heart valve (THV) of choice for redo - TAVI is a complex decision and first reports have examined the use of the Sapien 3TM THV (Edwards Lifesciences; Irvine, CA, USA) in failed EvolutTM (Medtronic, Minneapolis, MN, USA) THV. However, several different technical approaches may be worth consideration, and the subject remains a matter of debate. A 73-year old female with previous coronary artery by-pass grafting (CABG), percutaneous coronary intervention (PCI) and TAVI with a 26 mm EvolutTM R THV presented with signs of heart failure. The clinical investigation revealed a severe restenosis of the THV valve and a stenosis of the left coronary main stem. The patient was successfully treated with PCI of the left main and, during the same procedure, underwent implantation of a 25 mm NavitorTM THV (Abbott; Chicago, Il, USA). This case presentation aims to illustrate the rationale of and necessary conditions for performing a TAVI-in-TAVI procedure with NavitorTM THV in a failed EvolutTM THV which, to our best knowledge, constitutes a novel approach to redo - TAVI.
- Open Access
- 21 November 2022
- Published by Elsevier in American Heart Journal
- Vol. 257, 41-50
International randomized trial on the effect of revascularization or optimal medical therapy of chronic total coronary occlusions with myocardial ischemia - ISCHEMIA-CTO trial – rationale and design
- 21 November 2022
- Published by Elsevier in American Heart Journal
- Vol. 257, 41-50
Open AccessInternational randomized trial on the effect of revascularization or optimal medical therapy of chronic total coronary occlusions with myocardial ischemia - ISCHEMIA-CTO trial – rationale and design
- 1 August 2021
- Published by Elsevier in International Journal of Cardiology
- Vol. 337, 29-37
Safety and efficacy of coronary sinus narrowing in chronic refractory angina: Insights from the RESOURCE study
- 1 August 2021
- Published by Elsevier in International Journal of Cardiology
- Vol. 337, 29-37
Safety and efficacy of coronary sinus narrowing in chronic refractory angina: Insights from the RESOURCE study
- Open Access
- 23 May 2021
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (27) , 2657-2664
Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention: insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
To compare coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for treatment of patients with heart failure due to ischaemic heart disease. We analysed all-cause mortality following CABG or PCI in patients with heart failure with reduced ejection fraction and multivessel disease (coronary artery stenosis >50% in ≥2 vessels or left main) who underwent coronary angiography between 2000 and 2018 in Sweden. We used a propensity score-adjusted logistic and Cox proportional-hazards regressions and instrumental variable model to adjust for known and unknown confounders. Multilevel modelling was used to adjust for the clustering of observations in a hierarchical database. In total, 2509 patients (82.9% men) were included; 35.8% had diabetes and 34.7% had a previous myocardial infarction. The mean age was 68.1 ± 9.4 years (47.8% were >70 years old), and 64.9% had three-vessel or left main disease. Primary designated therapy was PCI in 56.2% and CABG in 43.8%. Median follow-up time was 3.9 years (range 1 day to 10 years). There were 1010 deaths. Risk of death was lower after CABG than after PCI [odds ratio (OR) 0.62; 95% confidence interval (CI) 0.41–0.96; P = 0.031]. The risk of death increased linearly with quintiles of hospitals in which PCI was the preferred method for revascularization (OR 1.27, 95% CI 1.17–1.38, Ptrend < 0.001). In patients with ischaemic heart failure, long-term survival was greater after CABG than after PCI. Study flowchart, time-to-first-event curves through 10-year follow-up and risk-estimate for the primary endpoint – all – cause mortality. Study flowchart, time-to-first-event curves through 10-year follow-up and risk-estimate for the primary endpoint – all – cause mortality.
- 23 May 2021
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (27) , 2657-2664
Open AccessLong-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention: insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
To compare coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for treatment of patients with heart failure due to ischaemic heart disease. We analysed all-cause mortality following CABG or PCI in patients with heart failure with reduced ejection fraction and multivessel disease (coronary artery stenosis >50% in ≥2 vessels or left main) who underwent coronary angiography between 2000 and 2018 in Sweden. We used a propensity score-adjusted logistic and Cox proportional-hazards regressions and instrumental variable model to adjust for known and unknown confounders. Multilevel modelling was used to adjust for the clustering of observations in a hierarchical database. In total, 2509 patients (82.9% men) were included; 35.8% had diabetes and 34.7% had a previous myocardial infarction. The mean age was 68.1 ± 9.4 years (47.8% were >70 years old), and 64.9% had three-vessel or left main disease. Primary designated therapy was PCI in 56.2% and CABG in 43.8%. Median follow-up time was 3.9 years (range 1 day to 10 years). There were 1010 deaths. Risk of death was lower after CABG than after PCI [odds ratio (OR) 0.62; 95% confidence interval (CI) 0.41–0.96; P = 0.031]. The risk of death increased linearly with quintiles of hospitals in which PCI was the preferred method for revascularization (OR 1.27, 95% CI 1.17–1.38, Ptrend < 0.001). In patients with ischaemic heart failure, long-term survival was greater after CABG than after PCI. Study flowchart, time-to-first-event curves through 10-year follow-up and risk-estimate for the primary endpoint – all – cause mortality. Study flowchart, time-to-first-event curves through 10-year follow-up and risk-estimate for the primary endpoint – all – cause mortality.